Print Page   |   Contact Us   |   Sign In   |   Create a Profile
News & Press: Industry News

NeurOp Selects NP10679 as Development Candidate for SAH

Thursday, May 22, 2014   (0 Comments)
Posted by: Maria Thacker
Share |
ATLANTA, May 21, 2014 – NeurOp, Inc. has selected NP10679 as a development candidate for the prevention of ischemic damage and its consequences in persons receiving surgical treatment for subarachnoid hemorrhage (SAH). NP10679 is a GluN2B subunit-specific modulator designed to work at the site of ischemic insult.

NeurOp has begun late-stage preclinical development studies with this candidate with the goal to file an IND in 2015.

This news follows the publication of related research by NeurOp’s director of drug discovery, Scott J. Myers, Ph.D., in collaboration with a number of other scientists. In February, Neurocritical Care published their paper entitled “pH-Sensitive NMDA Inhibitors Improve Outcome in a Murine Model of SAH.”

The manuscript demonstrates that the use of a pH-dependent NMDA antagonist has the potential to work selectively in areas of ischemia known to undergo acidic pH shifts, which occur during SAH. Because of their regional selectivity, these NMDA antagonists may also be associated with fewer behavioral side effects than non-selective NMDA antagonists.

About NeurOp
NeurOp, Inc. is an Atlanta-based biopharmaceutical company developing new medicines for central nervous system disorders, including depression, neuropathic pain, ischemia (stroke), schizophrenia, and Alzheimer’s and Parkinson’s diseases. Its research targets various subunits of neuronal NMDA receptors and their potential therapeutic benefit. A research collaboration and licensing agreement with Bristol-Myers Squibb currently funds and supports development of NeurOp’s compounds for the treatment of depression and neuropathic pain. Multi-year funding from the NIH supports its ischemia and schizophrenia research. For more information, please visit www.neuropinc.com.


Contact:
Barney Koszalka, CEO
Phone: 404.941.2350

Source: http://www.neuropinc.com/news-detail.aspx?id=23

more Calendar

9/28/2016
Casino Night

9/28/2016
2016 Georgia Bio Innovation Summit

Membership Software Powered by YourMembership.com®  ::  Legal